Materialise (MTLS) Panoramica del titolo
Materialise NV fornisce strumenti software di produzione additiva e medicale e servizi di stampa 3D nelle Americhe, in Europa, in Africa e nell'Asia-Pacifico. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per MTLS dai nostri controlli di rischio.
MTLS Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Materialise NV
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$6.56 |
| Massimo di 52 settimane | US$7.00 |
| Minimo di 52 settimane | US$4.78 |
| Beta | 1.35 |
| Variazione di 1 mese | 19.93% |
| Variazione a 3 mesi | 21.03% |
| Variazione di 1 anno | 13.30% |
| Variazione a 3 anni | -18.00% |
| Variazione a 5 anni | -70.97% |
| Variazione dall'IPO | -44.87% |
Notizie e aggiornamenti recenti
Nuova narrazione • Jun 01
Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability
Catalysts About Materialise Materialise provides 3D printing software and services, with a particular focus on medical applications and industrial manufacturing. What are the underlying business or industry changes driving this perspective?
Nuova narrazione • May 17
Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside
Catalysts About Materialise Materialise provides software and manufacturing solutions for 3D printing, with a particular focus on medical applications, industrial production and related services. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 29
Materialise: The Medical Segment Alone Makes This A Buy
Summary Materialise receives a 'Buy' rating, driven by robust growth in its medical segment despite weakness in software and manufacturing. MTLS's medical segment boasts a 4-year CAGR of 16%, with management guiding for continued strong growth through FY2026. The company maintains a fortress balance sheet with €71m net cash and trades at a significant discount to sector peers on EV/Sales and EV/EBITDA. My €7.20/share target price reflects medical segment valuation, but risks include potential growth slowdown and further deterioration in non-medical segments. Read the full article on Seeking AlphaRecent updates
Nuova narrazione • Jun 01
Medical And Software Expansion Will Drive Stronger Margins And Earnings Durability
Catalysts About Materialise Materialise provides 3D printing software and services, with a particular focus on medical applications and industrial manufacturing. What are the underlying business or industry changes driving this perspective?Nuova narrazione • May 17
Cloud Software And Medical Constraints Will Pressure 3D Printing Adoption Yet Offer Gradual Upside
Catalysts About Materialise Materialise provides software and manufacturing solutions for 3D printing, with a particular focus on medical applications, industrial production and related services. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 29
Materialise: The Medical Segment Alone Makes This A Buy
Summary Materialise receives a 'Buy' rating, driven by robust growth in its medical segment despite weakness in software and manufacturing. MTLS's medical segment boasts a 4-year CAGR of 16%, with management guiding for continued strong growth through FY2026. The company maintains a fortress balance sheet with €71m net cash and trades at a significant discount to sector peers on EV/Sales and EV/EBITDA. My €7.20/share target price reflects medical segment valuation, but risks include potential growth slowdown and further deterioration in non-medical segments. Read the full article on Seeking AlphaArticolo di analisi • Nov 05
Materialise's (NASDAQ:MTLS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Materialise NV's ( NASDAQ:MTLS ) stock, leading do a rise in the share price after its recent...Articolo di analisi • Oct 06
Materialise NV's (NASDAQ:MTLS) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 54.9x Materialise NV ( NASDAQ:MTLS ) may be sending very bearish signals...Articolo di analisi • Jul 27
Analyst Estimates: Here's What Brokers Think Of Materialise NV (NASDAQ:MTLS) After Its Second-Quarter Report
Shareholders might have noticed that Materialise NV ( NASDAQ:MTLS ) filed its quarterly result this time last week. The...Articolo di analisi • Jul 25
Materialise (NASDAQ:MTLS) Is Looking To Continue Growing Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Articolo di analisi • May 04
After Leaping 28% Materialise NV (NASDAQ:MTLS) Shares Are Not Flying Under The Radar
Those holding Materialise NV ( NASDAQ:MTLS ) shares would be relieved that the share price has rebounded 28% in the...Seeking Alpha • Feb 24
Materialise: Manufacturing Headwinds Are A Distraction
Summary Materialise's share price dropped significantly after the company reported poor Q4 earnings, which were driven by European automotive market weakness. Despite recent challenges, Materialise's Medical segment continues to perform well and the transition of the Software segment to a subscription model is progressing. The Medical and Software segments are Materialise's primary value drivers and more than justify the company's current valuation. Issues with the Manufacturing segment may need to be resolved before the stock moves higher though. Read the full article on Seeking AlphaArticolo di analisi • Feb 13
Materialise NV's (NASDAQ:MTLS) P/E Is Still On The Mark Following 26% Share Price Bounce
Materialise NV ( NASDAQ:MTLS ) shareholders have had their patience rewarded with a 26% share price jump in the last...
Nuova narrazione • Feb 09
Launch Of Mimics Flow And ACTech Expansion Will Advance Personalized Medicine
Focus on personalized medical solutions and enhanced platforms could drive revenue growth and improve operational efficiencies and net margins.Articolo di analisi • Jan 31
Materialise NV (NASDAQ:MTLS) Shares Could Be 28% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Materialise fair value estimate is US$6.77 Materialise is...Articolo di analisi • Jan 07
These 4 Measures Indicate That Materialise (NASDAQ:MTLS) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Nov 07
Materialise NV's (NASDAQ:MTLS) 27% Jump Shows Its Popularity With Investors
Materialise NV ( NASDAQ:MTLS ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Seeking Alpha • Nov 04
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
Summary Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue. Despite the stock moving higher in recent weeks, Materialise remains deeply undervalued. Read the full article on Seeking AlphaArticolo di analisi • Nov 01
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) recently posted some strong earnings, and the market responded positively. We did some...Seeking Alpha • Oct 25
Materialise: Medical Business Unit Is The Hidden Value
Summary Materialise NV is a Belgian additive manufacturing company, showing a 14.18% CAGR in its Medical segment from FY18 to FY23. Despite mixed results in other segments, Materialise maintains profitability with positive FCF and a strong balance sheet, supported by €63 million in net cash. The company's strategic positioning in high-value sectors and steady growth, combined with a net cash position and positive FCF, highlight its upside potential. DCF analysis suggests Materialise is undervalued by 35-40%, justifying a "buy" rating due to its innovative edge and expanding market in healthcare. Read the full article on Seeking AlphaArticolo di analisi • Oct 25
Is There Now An Opportunity In Materialise NV (NASDAQ:MTLS)?
While Materialise NV ( NASDAQ:MTLS ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Seeking Alpha • Aug 01
Materialise Stock: Nearing An Inflection Point (Rating Upgrade)
Summary Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward. While Materialise's share price has moved higher recently, the prospect of solid growth and significantly higher margins are not priced into the stock. Read the full article on Seeking AlphaArticolo di analisi • Aug 01
The Return Trends At Materialise (NASDAQ:MTLS) Look Promising
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Seeking Alpha • Apr 26
Materialise Q1: Progress Against Headwinds
Summary Materialise NV faces a challenging demand environment and is transitioning to a cloud-based SaaS business model, impacting its financial performance. The software business is progressing slowly, while the medical business continues to perform well. The manufacturing business is struggling, but the startup of the expanded ACTech facility later in the year could change this. Macro headwinds and ongoing investments probably limit near-term upside. Longer term, Materialise appears deeply undervalued. Read the full article on Seeking AlphaArticolo di analisi • Apr 19
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) just reported healthy earnings but the stock price didn't move much. Investors are...Seeking Alpha • Feb 26
Materialise: Upside From A Transition To Profitability
Summary The demand environment continues to weigh on Materialise's business, although the Medical segment remains a standout, with strong growth and improving margins. The adoption of robotics in joint replacement surgeries poses a threat to Materialise's medical business, though. Investments in the CO-AM platform and the ACTech facility expansion should begin to pay off in 2024, supporting growth and Materialise's competitive position. Given Materialise's relatively low valuation and the potential for solid growth and improving margins, Materialise's stock should do well over the next 1-2 years. Read the full article on Seeking AlphaArticolo di analisi • Feb 23
Does Materialise (NASDAQ:MTLS) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 31
Materialise NV: Consolidation And New Developments To Emerge As A Rising Star In The Additive Manufacturing Industry
Summary Materialise NV currently exhibits better growth, margins and fundamentals than its main competitors, positioning itself well in an industry that is estimated to grow at a CAGR of 16% until 2032; The medical business unit (c.a. 38.5% of total revenues in 9M23) continues to achieve double-digit growth, with the appointment of the new CEO to focus strongly on this segment; Both the analysis of multiples and DCF here presented show that the current share valuation is 40-45% below its fundamental value. Read the full article on Seeking AlphaArticolo di analisi • Jun 14
Here's Why Materialise (NASDAQ:MTLS) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • May 23
Returns On Capital At Materialise (NASDAQ:MTLS) Paint A Concerning Picture
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Articolo di analisi • Mar 14
Health Check: How Prudently Does Materialise (NASDAQ:MTLS) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Nov 22
Materialise (NASDAQ:MTLS) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Sep 30
Materialise: Financials Remain Resilient
Summary Strategic initiatives set Materialise up for long-term growth and should lead to higher margins. How these initiatives will be received by customers remains to be seen though. In the near-term, investments are likely to weigh on margins whilst having little impact on growth. In the current environment this is unlikely to be well received by investors. Materialise is reasonably valued but a deterioration in economic conditions presents a significant downside risk. Materialise (MTLS) was a real narrative stock through the pandemic, with its valuation becoming completely detached from the fundamentals of the business. Despite facing headwinds from a weakening macro environment and high energy prices, Materialise will continue to benefit from secular growth in additive manufacturing and a rebound in automotive and aerospace manufacturing. Given the current valuation, Materialise’s stock should perform well over the long-term, although progress on the profitability front may be required before the stock moves higher. Materialise offers a range of additive manufacturing software as well as on demand parts printing. It segments its business into software, medical and manufacturing. They continue to build out the capabilities of their software platforms and are in the process of shifting towards higher value add manufacturing. CO-AM Platform Materialise will soon be introducing their CO-AM platform, which gives manufacturers cloud-based access to a range of software tools that enable them to plan, manage and optimize every stage of their operations. The CO-AM platform utilizes a datalake to connect all production tools and track operations, which aims to make optimizing operations simpler. Materialise will offer more than 25 software applications on its CO-AM platform, including integration with Magics; AM Watch for shopfloor data collection, and its Build Processors for connectivity with more than 150 different 3D printing systems. Figure 1: CO-AM Platform (source: Materialise) Materialise expects that the CO-AM platform will appeal to customers who operate a larger number of machines, with interest expected to come from something like 20% of the user base. Materialise’s Magics software is already widely used by larger additive manufacturing service organizations for data preparation, potentially giving the company a launchpad from which to introduce a more integrated solution. The CO-AM platform will help to advance the use of additive manufacturing in serial production by helping manufacturers achieve the consistent quality standards that are necessary in mass production. Serial production refers to the manufacturing of large quantities of goods in batches, often producing a range of goods using one machine. For example, serial production would generally be used for mass personalization manufacturing. From a financial perspective, Materialise's software segment is the most attractive part of the business, but growth has stagnated over the past few years. The CO-AM platform could reaccelerate Materialise's software revenue growth, but should also be supportive of its other segments. New Software Products Materialise continue to build on the functionality of their software with the introduction of Magics 26. Magics is software for data and build preparation, and Magics 26 combines support for native CAD workflows with its existing mesh capabilities. Magics 26 will incorporate the Siemens Parasolid kernel, opening up a range of new opportunities for users. Users can make adjustments to the original design files using CAD operations to increase printability. The adjusted file remains compatible with the PLM system and are easiest to use for post-processing steps such as CNC milling operations. Link3D Acquisition Materialise acquired Link3D in 2021 for 33.5 million USD. The acquisition will not have a material impact on revenues in the short-term and will be a drag on margins. In 2021, Link3D had revenues of 2.3 million USD and EBITDA losses of 4.6 million USD. Link3D provides software for digital manufacturing which will help Materialise develop their cloud-based platform, by integrating Link3D’s additive MES (Manufacturing Execution System) solution with Materialise's Magics software suite. MESs track the transformation of inputs into finished products and provide information that allows manufacturing operations to be optimized. Software Materialise sells software that is compatible with nearly all printer types to customers that own 3D printers in order to enhance their efficiency and throughput. Materialise offers two horizontal software platforms, Magics and Mimics. Materialise’s software offerings include: Software that converts a CAD file into a 3D printable format Software to optimize a specific 3D customer application Software to organize and integrate a "factory" of multiple printer types and brands Software revenue comes from software licenses, maintenance contracts and custom software development services with the majority of sales through Materialise's own sales force and a minority through system manufacturers. Medical Materialise produces both custom medical devices and software for making custom devices and helping doctors plan surgeries. 3D printing for medical applications is the fastest growing business at Materialise, driven largely by growing demand for 3D surgical implants. 3D printed medical devices at the moment are primarily surgical guides. In particular, CMF is the growth engine of the medical devices business. The medical business is also fairly exposed to elective surgeries, which was a large headwind early in the pandemic, but had more or less normalized by Q3 2020. Materialise's Mimics Suite realized revenues of almost 23 million Euros in 2021. Materialise is developing AI to support the planning of surgeries and the design of devices, in addition to introducing AR and VR functionality. Manufacturing Materialise utilizes its own printers to manufacture end-use parts and prototypes for customers, primarily in the medical devices and automotive fields. The key differentiating factors of Materialise's 3D printing service are: The size of printers and the prototypes and parts that it can produce via Mammoth stereolithography printers The speed and variety in which parts can be produced, with Materialise operating one of the largest 3D printing sites in the world with a range of printing technologies. Materialise's Manufacturing segment was the most negatively impacted by the pandemic, due in large part to its reliance on the automotive and aerospace sectors. Manufacturing revenue has now fully recovered, with Q2 2022 revenue exceeding Q2 2019 by more than 10%. There has been a substantial shift in the Manufacturing business which has driven this rebound though. The manufacturing business is benefitting from a post-COVID rebound in product development that leverages additive manufacturing for prototyping. Materialise is also doing well in small, certified manufacturing series production. Figure 2: Global Vehicle Production (source: Created by author using data from OICA) Figure 3: Boeing Plus Airbus Revenue (source: Created by author using data from company reports) The importance of the automotive sector to Materialise’s plastics manufacturing activities has declined over time. Industrial goods and medical device contract manufacturing projects grew 25% YoY in Q2 2022, while automotive projects remained stable at 2021’s depressed levels. Within automotive subcontracting, Materialise has instead chosen to focus on areas with better margins, like large stereo-lithography parts printed on their Mammoth printers. ACTech had a large legacy business involved in the development of new internal combustion engines for cars. The combination of diesel gate and the pandemic reduced ACTech’s turnover by approximately 50% in early 2020. ACTech has now pivoted from small cylinder blocks and turbochargers to complex casted components for electric car drive-trains and chassis. This shift has returned ACTech to pre-COVID revenues with a more favorable margin profile. The ACTech facility can now support the manufacture of a wider variety of components and larger components using sand 3D printing. Sand 3D printing uses a sand-like working medium with a polymer to bind the particles together. This can be used to produce finished products or molds for an alternative material to be poured into. This has opened new opportunities for Materialise in agricultural, mining, construction and marine vehicles, producing a small series of large engine parts. The complexity of these types of parts is increasing to improve the thermodynamic efficiency of engines, which necessitates the use of precision sand printing and casting small series parts. Sand printing, molds assembly, metal casting, and post processing steps, like CNC milling, are necessary competencies to support these types of operations, and Materialise believes that offering integrated solutions provides significantly more value to customers. To support this opportunity, Materialise is investing in an additional 9,000 square meter facility that will be dedicated to CNC milling and quality control operations. This facility will also create space for Materialise to increase sand printing, molds assembly and casting operations in the old plant. Materialise expects to invest 23 million Euro’s in the coming years, which will double ACTech’s capacity.Rendimenti per gli azionisti
| MTLS | US Software | US Mercato | |
|---|---|---|---|
| 7D | -0.8% | -10.7% | -3.3% |
| 1Y | 13.3% | -12.6% | 22.3% |
Ritorno vs Industria: MTLS ha superato il US Software che ha restituito -12.6 % nell'ultimo anno.
Rendimento vs Mercato: MTLS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 22.3 % nell'ultimo anno.
Volatilità dei prezzi
| MTLS volatility | |
|---|---|
| MTLS Average Weekly Movement | 5.2% |
| Software Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: MTLS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di MTLS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1990 | 2,556 | Brigitte de Vet-Veithen | www.materialise.com |
Materialise NV fornisce strumenti software di produzione additiva e medicale e servizi di stampa 3D nelle Americhe, in Europa, in Africa e nell'Asia-Pacifico. L'azienda opera attraverso tre segmenti: Materialise Software, Materialise Medical e Materialise Manufacturing. Il segmento Materialise Software offre software proprietario attraverso programmi e piattaforme che consentono e migliorano la funzionalità delle stampanti 3D e delle operazioni di stampa.
Materialise NV Riepilogo dei fondamenti
| MTLS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$386.26m |
| Utili (TTM) | US$11.63m |
| Ricavi(TTM) | US$308.82m |
32.9x
Rapporto P/E1.2x
Rapporto P/SMTLS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MTLS Conto economico (TTM) | |
|---|---|
| Ricavi | €267.53m |
| Costo del fatturato | €113.41m |
| Profitto lordo | €154.12m |
| Altre spese | €144.05m |
| Utili | €10.07m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 27, 2026
| Utile per azione (EPS) | 0.17 |
| Margine lordo | 57.61% |
| Margine di profitto netto | 3.76% |
| Rapporto debito/patrimonio netto | 21.1% |
Come si è comportato MTLS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/10 22:28 |
| Prezzo dell'azione a fine giornata | 2026/06/10 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Materialise NV è coperta da 11 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Baliotti | Brean Capital Historical (Janney Montgomery) |
| Robert Burleson | Canaccord Genuity |
| Troy Jensen | Cantor Fitzgerald & Co. |